Giorgio Trinchieri, MD, on Fecal Microbiota Transplant to Promote Immunotherapy Response


Giorgio Trinchieri, MD, of the National Cancer Institute’s Center for Cancer Research joined CancerNetwork® to discuss enhancing the gut microbiome by way of fecal transplant for better immunotherapy responses.

A new study suggests that for patients with cancers that do not respond to immunotherapy, adjusting the composition of microorganisms in the intestines, or the gut microbiome, through the use of a fecal transplant may help induce responses.

CancerNetwork® was joined by Giorgio Trinchieri, MD, chief of the Laboratory of Integrative Cancer Immunology in the National Cancer Institute’s Center for Cancer Research, who spoke about the study results.

“A fecal microbiota transplant is a procedure used quite often in medicine for certain infectious disease, and its basically a transfer of fecal preparation from a healthy individual, or in our case with cancer, a patient who has survived treatment,” Trinchieri explained.

In the study discussed, patients with advanced melanoma received a fecal transplant as Trinchieri described for the purposes of enhanced immunity. Six of 15 patients who initially did not respond to pembrolizumab (Keytruda) or nivolumab (Opdivo) showed either some reduction in the size of the tumor or long-term disease stabilization.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.


Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595-602. doi: 10.1126/science.abf3363

Related Videos
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.
Related Content